The genetic testing market in Saudi Arabia is expanding at a remarkable pace, driven by strong government investment in healthcare innovation, a rising awareness of hereditary diseases, and the nation’s strategic vision to position itself as a leader in genomic medicine within the Middle East. The Saudi Vision 2030 and the National Transformation Program have placed biotechnology, precision medicine, and genomics at the core of the country’s healthcare development plans. One of the most notable initiatives is the Saudi Human Genome Program (SHGP), which aims to sequence the genomes of thousands of Saudi citizens to identify genetic mutations responsible for hereditary and chronic diseases prevalent in the region. This ambitious project has not only accelerated the adoption of genetic testing in hospitals and laboratories but has also led to the creation of national databases that enhance disease prediction and prevention. The high incidence of inherited disorders such as thalassemia, sickle cell anemia, cystic fibrosis, and other autosomal recessive diseases often linked to consanguineous marriages has made genetic screening and counseling a crucial part of Saudi healthcare policy. Advanced diagnostic centers and research institutions like King Faisal Specialist Hospital and Research Centre (KFSHRC) and King Abdullah International Medical Research Center (KAIMRC) are leading the implementation of next-generation sequencing (NGS), carrier testing, and prenatal diagnostics, ensuring that Saudi citizens have access to world-class genomic services.According to the research report, "Saudi Arabia Genetic Testing Market Research Report, 2030," published by Actual Market Research, the Saudi Arabia Genetic Testing market is anticipated to grow at more than 15.99% CAGR from 2025 to 2030. The Saudi Arabian genetic testing market are growing rapidly as the country combines technological innovation with policy-driven healthcare modernization.

The government’s strong commitment to precision medicine and preventive healthcare has encouraged collaborations between local institutions and international biotech companies to develop advanced genetic panels tailored to the unique genetic profile of the Saudi population. One of the fastest-growing trends is the adoption of pharmacogenomics, allowing physicians to customize medication plans based on genetic compatibility, improving treatment outcomes and minimizing adverse drug reactions. In addition, oncogenetic testing is gaining momentum as cancer awareness rises, driving early detection and personalized therapeutic strategies. Ethical governance and privacy regulations are being strengthened under frameworks aligned with the Saudi Data and Artificial Intelligence Authority (SDAIA) to ensure responsible use of genetic data. Furthermore, the government’s support for premarital and neonatal genetic screening programs has significantly increased testing demand, reflecting its focus on reducing hereditary disease rates through early intervention. The integration of AI and digital health technologies in genetic diagnostics is another defining feature of the Saudi market, enabling faster interpretation and predictive analytics for complex genetic data.

Educational campaigns, along with partnerships between research centers, universities, and healthcare providers, are helping build public trust and awareness of the benefits of genetic testing. With continued investment in genomic infrastructure, a skilled scientific workforce, and a commitment to health innovation, Saudi Arabia is rapidly emerging as a regional powerhouse in genetic testing and precision medicine setting a benchmark for integrating genomics into national healthcare and improving the genetic well-being of future generations.The product segment comprises genetic testing kits, reagents, sequencing platforms, bioinformatics software, and laboratory consumables used for clinical diagnostics and research. With Saudi Arabia’s growing focus on biotechnology and precision medicine under Vision 2030, the government has significantly increased investment in genomic infrastructure and research. Leading hospitals such as King Faisal Specialist Hospital and Research Centre (KFSHRC) and King Abdullah International Medical Research Center (KAIMRC) have adopted advanced sequencing platforms from global suppliers like Illumina, Thermo Fisher Scientific, and Qiagen. These products are essential for conducting genome sequencing, cancer diagnostics, and hereditary disease testing. On the other hand, the services segment dominates the Saudi market, supported by a growing network of specialized genetic laboratories and healthcare institutions offering a range of clinical and diagnostic services.

Public and private healthcare providers such as Saudi Diagnostics, Al Borg Laboratories, and AlMaha Labs are expanding their offerings to include comprehensive genomic and molecular testing services for oncology, reproductive health, and rare diseases. The country’s increasing healthcare digitalization and telemedicine adoption are also enhancing service accessibility. Furthermore, government initiatives such as the Saudi Human Genome Program (SHGP) have been pivotal in propelling the services segment, with the goal of sequencing hundreds of thousands of Saudi genomes to understand genetic diseases prevalent in the population. The demand for professional counseling and clinical interpretation services has risen as awareness about hereditary diseases and preventive healthcare expands among the Saudi population.Next-Generation Sequencing (NGS) is emerging as the cornerstone technology for genetic testing in the Kingdom, given its ability to sequence entire genomes rapidly and cost-effectively. NGS is increasingly used in oncology, rare disease diagnostics, and pharmacogenomics, supported by national projects like the Saudi Human Genome Program, which focuses on identifying genetic mutations unique to the Saudi population. Polymerase Chain Reaction (PCR) remains the most widely adopted technique due to its speed, sensitivity, and affordability.

PCR testing is prevalent in hospital laboratories across Riyadh, Jeddah, and Dammam, particularly for infectious diseases, hereditary disorders, and prenatal screenings. The success of PCR during the COVID-19 pandemic further strengthened the Kingdom’s molecular diagnostics infrastructure, paving the way for its application in genetic testing. Microarray technology plays a significant role in cytogenetic and pharmacogenomic studies, supporting research in population genetics and personalized medicine. In-situ Hybridization (ISH), especially Fluorescent In-Situ Hybridization (FISH), is primarily used for cancer diagnosis and chromosomal analysis in genetic disorders. Emerging technologies such as digital PCR, long-read sequencing, and AI-driven bioinformatics are gradually being adopted in academic and research institutions for higher accuracy and data integration. Saudi Arabia’s commitment to establishing genomic databases, investing in bioinformatics infrastructure, and training local professionals in genomics has accelerated the adoption of these advanced techniques.

Regulatory bodies such as the Saudi Food and Drug Authority (SFDA) and the Ministry of Health (MOH) are actively standardizing laboratory practices to ensure test reliability and safety.Oncology testing leads the market as cancer incidence rises across the Kingdom, prompting hospitals and research centers to integrate genomic testing into cancer care. Genetic profiling enables clinicians to identify actionable mutations and personalize treatment plans for cancers such as breast, colorectal, and leukemia. Advanced facilities such as King Abdullah Medical City and KFSHRC are at the forefront of implementing NGS-based tumor profiling and companion diagnostics to improve patient outcomes. Reproductive health testing is another fast-growing application, driven by a strong cultural emphasis on family planning and the government’s focus on maternal and child health. Genetic screening for carrier status, non-invasive prenatal testing (NIPT), and preimplantation genetic testing (PGT) are gaining traction in fertility clinics and obstetrics centers to prevent hereditary disorders. Genetic disease testing also holds significant importance, as Saudi Arabia has one of the highest rates of consanguineous marriages globally, which contributes to a higher prevalence of inherited conditions such as thalassemia, cystic fibrosis, and metabolic disorders.

The Saudi Human Genome Program plays a central role in identifying the genetic basis of these disorders to facilitate early diagnosis and prevention. Additionally, pharmacogenomic testing is expanding as personalized medicine gains momentum in clinical practice, helping optimize drug selection and dosage for individual patients. Other applications, such as nutrigenomics, ancestry, and lifestyle genetics, are gradually emerging as public awareness of genetic health grows.Considered in this report• Historic Year: 2019• Base year: 2024• Estimated year: 2025• Forecast year: 2030Aspects covered in this report• Genetic Testing Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Type• Products (Consumables, Equipment)• ServicesBy Technique• Next-generation Sequencing (NGS)• Polymerase Chain Reaction• Microarrays• In-situ Hybridization• OthersBy Application• Oncology Testing• Reproductive Health Testing• Genetic Diseases (Rare & Common)• Other Clinical (Pharmacogenomics, etc.) .